|
Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis. |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate |
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Cerulean Pharma; Janssen Biotech; Labceutics; Pfizer |
Speakers' Bureau - Bayer; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi |
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis (Inst) |
|
|
Consulting or Advisory Role - Novartis (Inst) |
|
|
Consulting or Advisory Role - Novartis (Inst) |
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
Stock and Other Ownership Interests - Exelixis |
Travel, Accommodations, Expenses - Novartis |
|
|
Honoraria - Astellas Pharma; Medivation; Novartis |
Consulting or Advisory Role - Aveo; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer |
Research Funding - Medivation |